KIT and gastrointestinal stromal tumor: In this study, 21 patients underwent NGS of peripheral blood samples to explore the role of activation of other pathways in resistance to GIST besides secondary KIT gene mutation and whether other gene mutations could predict the efficacy of dasatinib treatment.